Literature DB >> 19208050

Human papillomavirus, current vaccines, and cervical cancer prevention.

Anne M Teitelman1, Marilyn Stringer, Tali Averbuch, Amy Witkoski.   

Abstract

Human papillomavirus infection, the most common sexually transmitted infection in the United States, is associated with the development of cervical cancer. The new human papillomavirus vaccine advances cervical cancer prevention; however, provider-recommended screening with Papanicolaou tests and lifestyle modifications are still needed. Widespread implementation of the vaccine and delivering cervical cancer screening to underserved populations remain a challenge. Nurses are ideally suited to address these needs by providing education to patients and families.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208050     DOI: 10.1111/j.1552-6909.2008.00304.x

Source DB:  PubMed          Journal:  J Obstet Gynecol Neonatal Nurs        ISSN: 0090-0311


  4 in total

1.  Health care providers' perspectives on low HPV vaccine uptake and adherence in Appalachian Kentucky.

Authors:  Katharine J Head; Robin C Vanderpool; Laurel A Mills
Journal:  Public Health Nurs       Date:  2013-04-08       Impact factor: 1.462

Review 2.  The role of human papillomavirus infection in breast cancer.

Authors:  Ting Wang; Peng Chang; Ling Wang; Qing Yao; Wen Guo; Jianghao Chen; Tristan Yan; Christopher Cao
Journal:  Med Oncol       Date:  2011-02-13       Impact factor: 3.064

3.  Specific genotypes of human papillomavirus in 125 high-grade squamous lesions and invasive cervical cancer cases from Congolese women.

Authors:  Luc Magloire Anicet Boumba; Lahoucine Hilali; Mustapha Mouallif; Donatien Moukassa; Moulay Mustapha Ennaji
Journal:  BMC Public Health       Date:  2014-12-23       Impact factor: 3.295

4.  Analysis of epidemiological trends in human papillomavirus infection among gynaecological outpatients in Hangzhou, China, 2011-2015.

Authors:  Lili Qian; Yu Zhang; Dawei Cui; Bin Lou; Yimin Chen; Ying Yu; Yonglin Liu; Yu Chen
Journal:  BMC Infect Dis       Date:  2017-06-05       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.